Christopher Cano Net Worth

Mr. Christopher Cano biography

Christopher Cano is the COO & VP of Bus. Devel. at Tff Pharmaceuticals Inc.

What is the salary of Mr Cano?

As the COO & VP of Bus. Devel. of Tff Pharmaceuticals Inc, the total compensation of Mr Cano at Tff Pharmaceuticals Inc is $343,125. There are 2 executives at Tff Pharmaceuticals Inc getting paid more, with Glenn R. Mattes having the highest compensation of $654,167.

How old is Mr Cano?

Mr Cano is 50, he's been the COO & VP of Bus. Devel. of Tff Pharmaceuticals Inc since . There are 3 older and 1 younger executives at Tff Pharmaceuticals Inc. The oldest executive at Tff Pharmaceuticals Inc is Glenn R. Mattes, 66, who is the Pres, CEO & Director.

What's Mr Cano's mailing address?

Christopher's mailing address filed with the SEC is 3801 S. CAPITAL OF TEXAS HWY, SUITE 330, , AUSTIN, TX, 78704.

Insiders trading at Tff Pharmaceuticals Inc

Over the last 5 years, insiders at Tff Pharmaceuticals Inc have traded over $27,239,579 worth of Tff Pharmaceuticals Inc stock and bought 1,894,491 units worth $5,305,961 . The most active insiders traders include Therapeutics, Inc. Lung, Aaron G.L. Fletcher, eHarlan F Weisman. On average, Tff Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $174,967. The most recent stock trade was executed by Harlan F Weisman on 15 August 2023, trading 600,000 units of TFFP stock currently worth $150,000.

What does Tff Pharmaceuticals Inc do?

tff pharmaceuticals, inc. is a clinical-stage biopharma company focused on developing and commercializing drug products based on its patented thin film freezing (tff) technology. our patented thin film freezing (tff) platform makes it possible to turn more molecules into inhalable therapies. this novel technology provides high absorption and yield, uniform particle size, gentle process and endless possibilities. tff pharmaceuticals has two lead drug candidates: voriconazole inhalation powder and tac-lac inhalation powder. the company plans to add to this pipeline by collaborating with large pharmaceutical partners. the tff platform is protected by 42 patents issued or pending in the us and internationally.

Tff Pharmaceuticals Inc executives and stock owners

Tff Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Glenn R. Mattes,
  Pres, CEO & Director
• Kirk Allen Coleman,
  CFO, Treasurer & Sec.
• Christopher Cano,
  COO & VP of Bus. Devel.
• Paul F. Manley,
  Head of Regulatory Affairs
• Dr. Anthony J. Hickey Ph.D.,
  Chief Scientific Officer
• Dr. Dale Christensen,
  Director of Clinical Devel.
• Dr. James Brian Windsor Ph.D.,
  Chief Science Officer & Director
• Dr. James Brian Windsor,
  Chief Science Officer & Director
• Malcolm Fairbairn,
  Director
• Zamaneh Mikhak,
  Chief Medical Officer
• Robert S Mills,
  Director
• Glenn R. Mattes,
  President and CEO
• James Brian Windsor,
  Chief Science Officer
• Aaron G.L. Fletcher,
  Director
• Randy H Thurman,
  Director
• Brandi Roberts,
  Director
• Stephen Rocamboli,
  Director
• Therapeutics, Inc. Lung,
  10% owner
• Michael A Patane,
  Director
• Catherine Chai Zon Lee,
  Director
• Christopher Cano,
  Chief Operating Officer
• Harlan F Weisman,
  President and CEO
• Kirk Allen Coleman,
  Chief Financial Officer
• Capital L P Double Black Di...,
  
• Thomas Braxton King,
  Director